Expression of DBC1 is associated with nuclear grade and HER2 expression in breast cancer

  • Authors:
    • Haruko Hiraike
    • Osamu Wada-Hiraike
    • Shunsuke Nakagawa
    • Shigehira Saji
    • Daichi Maeda
    • Yuichiro Miyamoto
    • Kenbun Sone
    • Michihiro Tanikawa
    • Katsutoshi Oda
    • Keiichi Nakagawa
    • Tetsu Yano
    • Masashi Fukayama
    • Yuji Taketani
  • View Affiliations

  • Published online on: August 12, 2011     https://doi.org/10.3892/etm.2011.333
  • Pages: 1105-1109
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

DBC1/KIAA1967 (deleted in breast cancer 1) is a putative tumor-suppressor gene cloned from breast cancer specimens and is reported to regulate p53-dependent apoptosis through its specific inhibition of SIRT1 deacetylase. Although SIRT1 plays a pivotal role in carcinogenesis by regulating cellular proliferation, survival and death, its role in breast cancer remains controversial. Therefore, we aimed to investigate the expression status and clinicopathological significance of DBC1 and SIRT1 in breast cancer tissues. We evaluated the expression of DBC1 and SIRT1 in breast core-needle biopsy specimens from 48 primary breast cancer patients between 2005 and 2008. These patients were treated with primary systemic chemotherapy and subsequent surgical resection of the lesions. Immunohistochemical expression scores of DBC1 and SIRT1 were evaluated, and the relationship between their expression levels and clinicopathological features of breast cancer was analyzed. The expression was observed exclusively in the nuclei of normal and neoplastic ductal cells. In breast biopsy specimens, positive expression of DBC1 and SIRT1 was noted in 85 and 98% of patients, respectively. Expression of DBC1 was significantly associated with the tumor nuclear grade (P=0.019). DBC1 and SIRT1 expression was inversely correlated with HER2 expression (P=0.026 and 0.003, respectively). Lower expression of DBC1 and SIRT1 indicated a tendency for a favorable pathological response to chemotherapy, although this was not statistically significant. Our results reveal that the expression of DBC1 and SIRT1 in breast tissues is associated with tumor characteristics.
View Figures
View References

Related Articles

Journal Cover

November-December 2011
Volume 2 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hiraike H, Wada-Hiraike O, Nakagawa S, Saji S, Maeda D, Miyamoto Y, Sone K, Tanikawa M, Oda K, Nakagawa K, Nakagawa K, et al: Expression of DBC1 is associated with nuclear grade and HER2 expression in breast cancer. Exp Ther Med 2: 1105-1109, 2011.
APA
Hiraike, H., Wada-Hiraike, O., Nakagawa, S., Saji, S., Maeda, D., Miyamoto, Y. ... Taketani, Y. (2011). Expression of DBC1 is associated with nuclear grade and HER2 expression in breast cancer. Experimental and Therapeutic Medicine, 2, 1105-1109. https://doi.org/10.3892/etm.2011.333
MLA
Hiraike, H., Wada-Hiraike, O., Nakagawa, S., Saji, S., Maeda, D., Miyamoto, Y., Sone, K., Tanikawa, M., Oda, K., Nakagawa, K., Yano, T., Fukayama, M., Taketani, Y."Expression of DBC1 is associated with nuclear grade and HER2 expression in breast cancer". Experimental and Therapeutic Medicine 2.6 (2011): 1105-1109.
Chicago
Hiraike, H., Wada-Hiraike, O., Nakagawa, S., Saji, S., Maeda, D., Miyamoto, Y., Sone, K., Tanikawa, M., Oda, K., Nakagawa, K., Yano, T., Fukayama, M., Taketani, Y."Expression of DBC1 is associated with nuclear grade and HER2 expression in breast cancer". Experimental and Therapeutic Medicine 2, no. 6 (2011): 1105-1109. https://doi.org/10.3892/etm.2011.333